TY - JOUR
T1 - MalDA, Accelerating Malaria Drug Discovery
AU - Yang, Tuo
AU - Ottilie, Sabine
AU - Istvan, Eva S.
AU - Godinez-Macias, Karla P.
AU - Lukens, Amanda K.
AU - Baragaña, Beatriz
AU - Campo, Brice
AU - Walpole, Chris
AU - Niles, Jacquin C.
AU - Chibale, Kelly
AU - Dechering, Koen J.
AU - Llinás, Manuel
AU - Lee, Marcus C. S.
AU - Kato, Nobutaka
AU - Wyllie, Susan
AU - McNamara, Case W.
AU - Gamo, Francisco Javier
AU - Burrows, Jeremy
AU - Fidock, David A.
AU - Goldberg, Daniel E.
AU - Gilbert, Ian H.
AU - Wirth, Dyann F.
AU - Winzeler, Elizabeth A.
N1 - Funding Information:
The complete list of authors includes those named in the author list, as well as the members of the Malaria Drug Accelerator Consortium, which include John Okombo, Manu Vanaerschot, Charisse Flerida A. Pasaje, Krittikorn Kumpornsin, James M. Murithi, Jessica L. Bridgford, Tarrick Qahash, Edward Owen, Lauren Arendse, Kathryn Wicht, Victor Corpas Lopez, and Rachel Milne. T.Y. and S.O. are supported by grants from BMGF (OPP1054480). E.A.W. is supported by grants from the National Institutes of Health (NIH) (R01 AI152533, R01 AI152551), the BMGF (OPP1054480), and MMV. D.A.F. gratefully acknowledges funding from the MMV and the NIH (R01 AI50234, R01 AI124678). B.B, S.W. and I.H.G are supported by a Wellcome Trust Centre Award [203134/Z/16/Z]. Figures were created with BioRender.com. K.J.D. holds stock in TropIQ Health Sciences. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Copyright:
© 2021 The Authors
PY - 2021/6
Y1 - 2021/6
N2 - The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
AB - The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
KW - MalDA
KW - Plasmodium falciparum
KW - drug resistance
KW - malaria
KW - target-based drug discovery
UR - http://www.scopus.com/inward/record.url?scp=85101721246&partnerID=8YFLogxK
U2 - 10.1016/j.pt.2021.01.009
DO - 10.1016/j.pt.2021.01.009
M3 - Review article
C2 - 33648890
SN - 1471-4922
VL - 37
SP - 493
EP - 507
JO - Trends in Parasitology
JF - Trends in Parasitology
IS - 6
ER -
